Trials / Completed
CompletedNCT02998099
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP SINGLE-DOSE STUDY TO ESTIMATE THE EFFECT OF AGE ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF INTRAVENOUS RIVIPANSEL (PF-06460031)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- GlycoMimetics Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of age on PK, safety and tolerability of IV rivipansel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivipansel | A single dose of IV rivipansel over 20 minutes. |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-02-01
- Completion
- 2017-03-01
- First posted
- 2016-12-20
- Last updated
- 2020-06-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02998099. Inclusion in this directory is not an endorsement.